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ABSTRACT 
Medication backorders and shortages may contribute to an increase in the overall cost of 
healthcare by increasing the cost to deliver care. Drug manufacturers face little regulatory 
pressure to provide immediate notice to the healthcare industry regarding anticipated supply 
issues. These supply issues impact the finances of hospitals and the care patients receive. 
Particularly, supply issues effecting life-saving medications, like antibiotics, are of public health 
relevance as they have the greatest potential to impact the delivery of healthcare. Although the 
public health impact is mostly understood, the exact financial impact of medication backorders is 
not well-defined. The purpose of this study is to quantify the financial burden of medication 
backorders and shortages to a large, tertiary care hospital in Pittsburgh, Pennsylvania.  
Medication backorders and shortages have steadily increased in the past decade, requiring 
healthcare institutions to be proactive in order to prevent shortages from effecting patient care 
outcomes. The primary objective of this study is to determine the percent change in direct drug 
prices pre- and post-backorder. The secondary objectives are to evaluate the change in labor 
costs associated with preparing medication products and the overall percent change in costs 
(direct drug price and labor costs combined) pre- and post-backorder.  
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1.0 PURPOSE 
Medication backorders or shortages are defined by American Society of Health-System 
Pharmacists (ASHP) as “a supply issue that affects how the pharmacy prepares or dispenses a 
drug product or influences patient care when prescribers must use an alternative agent.”1 The 
terms medication backorder and medication shortage will be used interchangeably throughout 
this paper because the net effect to a health-system is the same for each situation.  
In the past decade, the number of medications effected by a backorder has steadily 
increased, increasing the amount of resources required to address gaps in care left by dwindling 
drug stock.
2
 Many causes of medication backorders have been identified, including: raw or bulk 
material shortage, regulatory issues delaying manufacture of product, voluntarily medication 
recall by drug companies, formulation change requiring new production practices, manufacturer 
business decisions, unexpected increases in demand for drug, and natural disasters.
3
  
It is estimated drug shortages are associated with an annual cost of $216 million in the 
United States and approximately $37,951 annually for hospitals with 200-399 beds.
1
 Larger 
hospitals spend more time managing drug backorders compared to smaller hospitals.
1 
At the 
study location, there is a medication backorder committee that tracks stock levels and creates 
recommendations on how to manage backorders when one arises.  
 2 
Medication backorders are often inconvenient and have the potential to impact patient 
care and hinder cost containment efforts – making backorders and shortages of significant public 
health relevance.
4
 Injectable products comprise about 80% of medication backorders, including 
life-extending chemotherapy agents and life-saving antibiotics.
5
 These medication categories are 
of particular concern because availability issues of injectables may endanger patient lives.
5
 
While the public health impact of shortages is recognized, the exact financial impact of 
medication backorders is not known. This project will estimate and summarize the financial 
impact of medication backorders at a tertiary care hospital in Pittsburgh, Pennsylvania by 
identifying factors that potentially increase drug costs as a result of medication backorders, 
including quantifying labor expenditures. It is expected that the cost to prepare a dose of 
medication effected by a backorder will be greater post-backorder than pre-backorder.  
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2.0 METHODS 
This study is a single-center retrospective analysis of medications currently or recently on 
backorder within the past 24 months. The study methods were submitted to the Institutional 
Review Board and received exemption due to minimal risk identified.  
In order to be included in the study analysis, an intervention must have been implemented 
as a result of a backorder and the medication had at least 20 charted doses in the computerized 
physician order entry (CPOE) system per month. Non-formulary medications and medications 
with an intervention lasting less than three months were excluded from analysis.  
All medications provided by the pharmacy department have a potential to be effected by 
a medication shortage and thus had the potential to be included in study analysis. Most 
medications effected by a shortage at this specific institution, and nationally, are intravenous 
products. However, all products are tracked and evaluated by the medication backorder 
committee, including: topical agents, oral formulations, suppositories, ophthalmic solutions, otic 
solutions, etc.  
A total of eight medications were evaluated for inclusion. Six medications were excluded 
and two were included in analysis. The most common reason for exclusion was an intervention 
which did not last for at least three months. Two evaluated medications met inclusion criteria and 
were included in analysis. 
 4 
 
 
 
 
 
 
 
Pre- and post-backorder usage and pricing information was collected for a three month 
time period, before and after implementation of the backorder intervention, using the CPOE 
system and inventory records, respectively. Observation of current preparation times for identical 
delivery methods were used to extrapolate and determine pre- and post-backorder labor costs. 
For example, if a product was previously prepared using a needle-less sterile preparation 
product, that delivery method for another drug was observed, timed, and assumed to be 
equivalent to the pre-backorder preparation time. Additionally, CPOE documentation was 
utilized to determine pharmacist time required to ensure compliance with the medication 
backorder committee’s intervention.   
Monetary values were assigned to the labor times using national wage medians from the 
United States Bureau of Labor and Statistics. Descriptive statistics was generated from the 
collected data. Means and medians were used when appropriate. It was expected that post-
backorder costs would be greater than pre-backorder costs.  
Figure 1. Inclusion Criteria 
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3.0 RESULTS 
Two medications met inclusion criteria: desmopressin acetate and amiodarone 
hydrochloride. For both medications, only the intravenous preparations met inclusion criteria. 
Data was evaluated individually for each medication and the backorder cost comparison is 
reported for each medication separately.  
The manufacturer of desmopressin acetate ceased production of the 4 mcg vial used to 
prepare intravenous (IV) products. The hospital was forced to purchase a more expensive, brand 
only product which was also on backorder due to increased demand. The post-backorder average 
wholesale price (AWP) of one vial was $84/vial. The backorder committee proposed measures 
that would reduce overall use of desmopressin in order to minimize the increased costs 
associated with switching manufacturers.  
The hospital Pharmacy and Therapeutics Committee approved the medication backorder 
committee’s three-part intervention plan, which included: dosing based on patient’s ideal body 
weight (instead of actual body weight), a maximum dose of 20 mcg, and rounding of all doses to 
the nearest vial size. These interventions were targeted at reducing use and waste of the drug.   
Data collected for desmopressin acetate included usage data and pharmacist intervention 
time pre- and post-backorder. Monetary values were assigned to the pharmacist intervention time 
using national wage median ($57.20/hour).
6
 Table 1 lists the percent change in institutional price 
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and cost of a medication dose pre- and post-backorder. The price and cost to prepare a single 
dose of desmopressin acetate was higher post-backorder. Applying these percentages to the 
AWP of a single vial, the cost increase was annualized.  
 
Table 1. Desmopressin Acetate Results 
Primary Objective  
 Pre-
Backorder 
Post-
Backorder  
Total Charted Doses 89 70 
Median Dose (range) 23 mcg (10-40)  20 mcg (12-26) 
Percent Change in Price per Dose (price 
increase) 
  
249% ($299.70
+
) 
Secondary Objectives   
RPh Interventions*, n=22  $111.55 
Percent Change in Cost per Dose  252% ($301.29
+
) 
Annual Cost Increase  $84,361.20*
+
 
*5 min per intervention and salaries equivalent to national medians per US Bureau of Labor and Statistics 
+
Based on current Average Wholesale Price (AWP) of $84/vial per inventory records 
 
Amiodarone hydrochloride intravenous (IV) drips were prepared using a sterile, needle-
less connector which allowed the vial to be connected to a bag of diluent without mixing. This 
method enabled the product to be prepared in batches in the pharmacy and stored in automatic 
dispensing cabinets (ADCs). Nursing personnel would obtain the product from ADCs and 
activate the bag by enabling the mixing mechanism. The bag used with the needle-less 
preparation system went on backorder and was no longer available for hospital staff to order.  
As a result of the backorder, preparation of amiodarone hydrochloride IV drips was 
moved to the IV Room where doses were compounded to fill patient-specific orders. Direct drug 
prices included all products required to prepare a single dose (diluent bag, drug, connectors, 
etc.). Labor costs were measured by observations of pharmacy staff preparing and checking drips 
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batched using a needle-less preparation system (pre-backorder method) and compounded IV 
drips (post-backorder method).  
Price and cost to prepare a single dose of amiodarone hydrochloride drips were higher 
post-backorder. The AWP for a single dose post-backorder was $11.56 per dose and this data 
was used to annualize the cost increase.  
Table 2. Amiodarone Hydrochloride Results 
Primary Objective  
 Pre-Backorder Post-Backorder  
Total Charted Doses 699 498 
Percent Change in Price per 
Dose 
 67% ($4.09
+
) 
Secondary Objectives   
Pharmacist Check* 0.23 min ($0.22)  0.89 min ($0.85)  
Technician Preparation*  0.91 min ($0.25) 2 min ($0.56) 
Labor Costs per dose (annual 
cost)  
$0.47 ($1,314.12) $1.41 ($2,808.72) 
Percent Change in Cost per 
Dose 
 78% ($5.03
+
) 
Annual Cost Increase  $10,019.76*
+
 
*Salaries based on values from US Bureau of Labor and Statistics
7
 
+
Based on current AWP of $11.56/dose for preparation products 
 
The price and cost to prepare a single dose of amiodarone hydrochloride was higher post-
backorder. Applying these percentages to the AWP of a single dose of the product, the cost 
increase was annualized.  
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4.0 CONCLUSION  
One predominant limitation to this study was the small number of medications that met 
inclusion criteria and were ultimately evaluated. Another limitation is the study methods did not 
enable investigators to capture doses that were not charted as given in the computerized 
physician order entry (CPOE) system or wasted doses.  
Additionally, the medication backorder committee’s time, spent managing backorders 
and creating action plans in concert with key prescribers, was excluded from analysis. Lastly, 
data was collected from current labor efforts and assumed these times to be equivalent to pre-
backorder preparation times.  
Analysis of financial changes pre- and post-backorder of desmopressin acetate and 
amiodarone hydrochloride suggest that a medication backorder will lead to an increase in cost to 
prepare a medication. Factors contributing to increased costs include the price of the drug 
products and increased labor efforts to prepare the product.  
This study supports the notion that drug shortages are a significant public health concern 
as shortages may hinder cost containment efforts of healthcare providers. Increases in drug costs 
ultimately increase the cost to provide patient care; these costs may eventually transfer to the 
patient in the form of higher premiums and deductibles.  
 9 
The information obtained through this study will be incorporated into the analysis of 
future medication backorders within the study institution. By identifying factors contributing to 
increased drug costs and quantifying these increases, the most cost-effective or cost-neutral 
recommendation can be implemented. However, medication shortages pose a greater public 
health concern when patient care is rationed, delayed, or denied due to a specific medication not 
being available. Future investigations should be conducted to understand the impact of 
medication shortages on patient care and patient outcomes. 
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